Kalif Eliyahu Sharon 4

What Happened
Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd (TEVA), sold 106,563 ordinary shares (which may be represented by American Depositary Shares) in an open-market transaction on June 11, 2026. The reported weighted-average sale price was $34.10 per share for total proceeds of approximately $3,633,308. The filing characterizes the entry as a sale (S).

Key Details

• Transaction date: June 11, 2026. Filing date: June 16, 2026 (filed five calendar days after the trade; appears to be one business day later than the typical two-business-day Form 4 deadline).
• Quantity and price: 106,563 shares sold; weighted-average price $34.10; reported execution prices ranged from $33.985 to $34.25 (footnote offers to provide per-price breakdown on request).
• Total value: ≈ $3,633,308.
• Mechanism: Open-market sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 26, 2025.
• Shares owned after transaction: Not specified in the data provided in this summary.
• Other note: Ordinary shares may be represented by ADSs (each ADS currently represents one ordinary share).

Context
This was a prearranged sale under a 10b5-1 plan, which means the trades were executed according to a prior written plan and are generally treated as routine rather than an immediate expression of the insider’s view of the stock. Sales do not necessarily signal negative company prospects; retail investors often view purchases as more informative about insider confidence.